# Praxis Precision Medicines, Inc. Common Stock (PRAX)

> Praxis Precision Medicines, Inc. Common Stock (PRAX) trades at $312.49 (+2.44%) as of 6:35:12 AM EST on Nov 19, 2026, +15.39% over the past month. Market cap is $8.53B, with 8.7 days to cover in short interest.

Canonical: https://massive.com/quote/prax
Data as of: 2026-11-19T11:35:12.914Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$312.49** +7.43 (+2.44%)
As of 6:35:12 AM EST on Nov 19, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Praxis Precision Medicines, Inc. Common Stock (PRAX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +0.04% |
| 1W | -11.85% |
| 1M | +15.39% |
| YTD | +3.55% |
| 1Y | +85.99% |
| 52-wk range | $160.11 – $392.70 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for PRAX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $302.82 – $314.72 |
| Open | $304.36 |
| Prev close | $305.06 |
| Volume | 425.75K |
| Market cap | $8.53B |
| Shares out | 27.95M |

## Valuation and profitability ratios

Valuation and profitability ratios for Praxis Precision Medicines, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 6.77 |
| P/FCF | — |
| ROE | -28.5% |
| ROA | -27.4% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 18, 2026

## Insider trading

[Praxis Precision Medicines, Inc. Common Stock (PRAX) insider trading](https://massive.com/quote/prax/insider-trading.md): open-market Form 4 buys and sells by Praxis Precision Medicines, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Praxis Precision Medicines, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 12, 2026 · Partnership or collaboration
  “The Company continues to make progress on its recent collaboration with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide. The patch is designed to improve accessibility for ulixacaltamide and is planned to enter the clinic in 2027.”
- Nov 9, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 9, 2026, Praxis Precision Medicines, Inc. announced its financial results for the quarter ended September 30, 2026.”
- Aug 6, 2026 · Investor presentation
  “On August 6, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available in the "Investors + Media" portion of the Company's website at investors.praxismedicines.com and a copy is furnished as Exhibit 99.2 to this Current Report.”
- Jul 7, 2026 · Partnership or collaboration
  “the Company entered into a research collaboration and license agreement (the "Agreement") with Remagine Labs, Inc., a developer of electronically controlled transdermal drug delivery systems ("Remagine"), to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide for essential tremor. Under the Agreement, the Company and Remagine will collaborate to apply Remagine's proprietary platform, designed for precise, multi-day active transdermal dosing, to ulixacaltamide”
- Jul 2, 2026 · [New auditor engagement](https://massive.com/quote/sec-filings/8-k/auditor-changes.md)
  “On June 29, 2026, the Audit Committee approved the engagement of KPMG LLP ("KPMG") as the Company's new independent registered public accounting firm, effective as of that date.”

## Dividend history and stock splits

Praxis Precision Medicines, Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-15 · Nov 29, 2023

## PRAX short interest

How heavily PRAX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 8.7 |
| Short interest | 4.21M |
| Avg volume | 484.39K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## PRAX news

The latest news and headlines about Praxis Precision Medicines, Inc. Common Stock (PRAX).

- [Why Is Praxis Precision Stock Soaring Tuesday?](https://www.benzinga.com/news/fda/26/04/51814850/why-is-praxis-precision-stock-soaring-tuesday?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Apr 14, 2026 · positive sentiment
- [Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy](https://www.globenewswire.com/news-release/2026/04/06/3268372/0/en/Praxis-Precision-Medicines-Announces-Positive-Results-from-the-EMBRAVE-Part-A-Trial-of-Elsunersen-in-Patients-with-SCN2A-Early-Onset-Developmental-and-Epileptic-Encephalopathy.html) · GlobeNewswire Inc. · Apr 6, 2026 · positive sentiment
- [This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter](https://www.fool.com/coverage/filings/2026/03/16/this-biotech-stock-up-700-is-still-a-top-holding-despite-a-usd9-3-million-sale-last-quarter/?source=iedfolrf0000001) · The Motley Fool · Mar 16, 2026 · positive sentiment
- [Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline](https://www.fool.com/coverage/filings/2026/03/13/praxis-stock-has-surged-700-in-a-year-and-this-fund-is-betting-usd266-million-on-its-pipeline/?source=iedfolrf0000001) · The Motley Fool · Mar 13, 2026 · positive sentiment
- [Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings](https://www.fool.com/coverage/filings/2026/03/13/biotech-stock-up-685-draws-usd80-5-million-investment-amid-dual-fda-filings/?source=iedfolrf0000001) · The Motley Fool · Mar 13, 2026 · positive sentiment

## About Praxis Precision Medicines, Inc. Common Stock

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 11K |
| Listed | Oct 16, 2020 |

[Company website](https://www.praxismedicines.com)

## FAQ

### What is the Praxis Precision Medicines, Inc. Common Stock (PRAX) stock price today?

Praxis Precision Medicines, Inc. Common Stock (PRAX) is trading at $312.49 (+2.44% on the day) as of 6:35:12 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Praxis Precision Medicines, Inc. Common Stock?

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance.

### What is the short interest in PRAX?

As of Oct 30, 2026, PRAX has 4.21M shares short and 8.7 days to cover.

### What exchange is PRAX listed on?

Praxis Precision Medicines, Inc. Common Stock (PRAX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time PRAX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=PRAX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Praxis Precision Medicines, Inc. Common Stock (PRAX) insider trading](https://massive.com/quote/prax/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
